Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sunitinib - Sarcomatrix Therapeutics

Next Previous
X
Search
Drug Profile

Sunitinib - Sarcomatrix Therapeutics

Latest Information Update: 14 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sarcomatrix Therapeutics
  • Developer National Center for Advancing Translational Sciences; Sarcomatrix Therapeutics
  • Class Amides; Antineoplastics; Ethylamines; Eye disorder therapies; Fluorobenzenes; Indoles; Pyrroles; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Colony-stimulating factor receptor antagonists; Fms-like tyrosine kinase 3 inhibitors; Integrin alpha7 stimulants; Platelet-derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto-oncogene protein c-kit inhibitors; Proto-oncogene protein c-ret inhibitors; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Duchenne muscular dystrophy
  • Research Cardiomyopathies

Most Recent Events

  • 03 Jan 2024 Early research in Cardiomyopathies in USA (unspecified route), prior to January 2024 (Sarcomatrix Therapeutics pipeline, January 2024)
  • 03 Jan 2024 Preclinical trials in Duchenne muscular dystrophy in USA (unspecified route), prior to January 2024 (Sarcomatrix Therapeutics pipeline, January 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top